Author

Bethany Beazley

DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE
DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, HISTOLOGIC, AND ENDOSCOPIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE

Bethany Beazley  et al.

DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS
DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Bethany Beazley  et al.

DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY
DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Bethany Beazley  et al.

DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
DUPILUMAB IMPROVES HISTOLOGICAL AND ENDOSCOPIC FEATURES OF EOSINOPHILIC OESOPHAGITIS IN CHILDREN AGED 1–11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

Bethany Beazley  et al.

Item 1 - 4 / 4
1